BioInvenu Corporation

About BioInvenu Corporation

BioInvenu is dedicated to developing assay products and services by utilizing a novel cell-based protein-protein interaction assay technology, LinkLight™ technology. The LinkLight™ technology was originally invented in Sanofi-Aventis. The technology utilizes protein-protein interactions as the functional signal readout. Protein-protein interaction is an essential cellular process regulating signal transductions in a living cell. Specific protein-protein interactions define signal transduction pathways. Ligand-induced transient protein-protein interactions are therefore of particular interest as the intervention points for drug discovery. The LinkLight™ technology has been applied to G-protein coupled receptors (GPCR), nuclear hormone receptors (NHR), and receptor tyrosine kinases (RTK) by utilizing receptor and its signal adaptor interaction as the functional signal readout. Biologically relevant compounds that modulate protein-protein interactions can be identified with this highly sensitive, specific, and robust assay method. The technology has the potential for applying a broad range of drug targets that are difficult to tackle by existing methods. In addition to finding molecules that modulate protein-protein interaction signal cascades, the technology can be applied to protein-protein interaction drug targets by identifying molecules directly blocking protein-protein interactions.

View contact profiles from BioInvenu Corporation